Results 21 to 30 of about 34,922 (258)

Levodopa-responsive chorea: A review

Annals of Indian Academy of Neurology, 2020
Background: Chorea is one of the disabling movement disorders, and the number of drugs which can treat this disorder effectively is limited. Tetrabenazine and deutetrabenazine are the two drugs approved by the US-FDA for the treatment of chorea ...
Mark Farrenburg, Harsh V Gupta
doaj   +1 more source

Experience in using levodopa-benserazide

Неврология, нейропсихиатрия, психосоматика, 2015
Levodopa remains the most effective drug for the treatment of Parkinson's disease. The paper considers the mechanism of action, recommended levodopa doses, the time of therapy initiation, and risk factors for motor complications.
Elena Anatolyevna Katunina, Yu. N. Bezdolnyi, E. A. Malykhina, N. V. Titova   +3 more
doaj   +1 more source

Exploring the levodopa-paradox of freezing of gait in dopaminergic medication-naïve Parkinson’s disease populations

npj Parkinson's Disease, 2023
The relationship between dopaminergic treatment and freezing of gait (FOG) in Parkinson’s disease (PD) is complex: levodopa is the most effective symptomatic treatment for FOG, but long-term pulsatile levodopa treatment has also been linked to an ...
Jamie A. F. Jansen, Tamine T. C. Capato, Sirwan K. L. Darweesh, Egberto R. Barbosa, Rogier Donders, Bastiaan R. Bloem, Jorik Nonnekes   +6 more
doaj   +1 more source

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients

Cells, 2022
The catechol-O-methyltransferase inhibitors entacapone and opicapone prolong the efficacy of conventional oral levodopa/dopa decarboxylase inhibitor formulations through an increase in levodopa plasma bioavailability.
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede   +3 more
doaj   +1 more source

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease

Frontiers in Neurology, 2021
Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of
Natalia Palacios, Natalia Palacios, Natalia Palacios, Anas Hannoun, Julie Flahive, Doyle Ward, Doyle Ward, Kelsey Goostrey, Anindita Deb, Kara M. Smith   +9 more
doaj   +1 more source

Identification of TH Variants in Chinese Dopa-Responsive Dystonia Patients and Long-Term Outcomes

Frontiers in Neurology, 2021
Background: Dopa-responsive dystonia (DRD) is a movement disorder that is highly clinically and genetically heterogeneous. Our study summarizes clinical characteristics and long-term outcomes in patients with dopa-responsive dystonia with the aim of ...
Xin-yao Li, Ying-mai Yang, Li-bo Li, Meng-yu Zhang, Yang-yu Huang, Jie Wang, Lin Wang, Xin-hua Wan   +7 more
doaj   +1 more source

Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments

Journal of Parkinson’s Disease, 2013
Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD). Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI ...
David Salat, Eduardo Tolosa
doaj   +1 more source

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa

ADMET and DMPK, 2022
Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah, Ofosua Adi-Dako, Benoit N’guessan, Kennedy Kwami Edem Kukuia, Benedicta Obenewaa Dankyi, Ismaila Adams, Ebenezer Ofori-Attah, Regina Appiah-Opong, Seth Kwabena Amponsah   +8 more
doaj   +1 more source

A regression analytical model of serum levodopa metabolic profile in Parkinson's disease

Heliyon
Although levodopa and its metabolites in blood have been investigated in parkinsonian disorders for biomarkers, medication effects of levodopa-associated drugs remain unclear. In this study, we investigated levodopa associated metabolites to characterize
Akiko Chukyo, Osamu Komori, Motoki Fujimaki, Naoko Kaga, Hikari Taka, Yuanzhe Li, Shin-Ichi Ueno, Haruka Takeshige-Amano, Manabu Funayama, Tomohiro Ishimaru, Hirofumi Teranishi, Taku Hatano, Kei-Ichi Ishikawa, Yutaka Oji, Taiji Tsunemi, Yuta Ishiguro, Kensuke Daida, Yoko Imamichi, Noriko Nishikawa, Takashi Ueno, Yoshiki Miura, Shogo Ohuchi, Tetsushi Kataura, Nobutaka Hattori, Shinji Saiki   +24 more
doaj   +1 more source

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease

Therapeutic Advances in Chronic Disease, 2019
Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Marianne Luinstra, Wijnand Rutgers, Teus van Laar, Floris Grasmeijer, Anja Begeman, Valmira Isufi, Luc Steenhuis, Paul Hagedoorn, Anne de Boer, Henderik W. Frijlink   +9 more
doaj   +1 more source